Lv5
942 积分 2023-08-16 加入
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program
1天前
已完结
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
7天前
已完结
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
7天前
已关闭
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
7天前
已完结
First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer
8天前
已完结
First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer
8天前
已完结
Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)
21天前
已完结
Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study
21天前
已完结
The use of pembrolizumab for the treatment of metastatic uveal melanoma
21天前
已完结
World’s first two iPSC therapies in Japan
24天前
已完结
皖公网安备34019202002308
